Palvella Therapeutics Names David W. Osborne, Ph.D. as Chief Innovation Officer
WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has appointed David W. Osborne, Ph.D., as Chief Innovation Officer, bringing more than 25 years of experience in developing therapies for difficult-to-treat …
Palvella Therapeutics Names David W. Osborne, Ph.D. as Chief Innovation Officer Read More